Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
IMUC's Cash to Debt is ranked higher than
89% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. IMUC: No Debt )
IMUC' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
IMUC's Interest Coverage is ranked higher than
86% of the 206 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. IMUC: No Debt )
IMUC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 11.47
M-Score: -3.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -36.50
IMUC's ROE (%) is ranked higher than
56% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.58 vs. IMUC: -36.50 )
IMUC' s 10-Year ROE (%) Range
Min: -2712.11   Max: -33.24
Current: -36.5

-2712.11
-33.24
ROA (%) -33.30
IMUC's ROA (%) is ranked higher than
54% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.35 vs. IMUC: -33.30 )
IMUC' s 10-Year ROA (%) Range
Min: -481.59   Max: -17.58
Current: -33.3

-481.59
-17.58
ROC (Joel Greenblatt) (%) -21969.57
IMUC's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.02 vs. IMUC: -21969.57 )
IMUC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -52960   Max: -517.5
Current: -21969.57

-52960
-517.5
EBITDA Growth (%) -20.60
IMUC's EBITDA Growth (%) is ranked higher than
54% of the 235 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. IMUC: -20.60 )
IMUC' s 10-Year EBITDA Growth (%) Range
Min: -32.2   Max: 102.7
Current: -20.6

-32.2
102.7
EPS Growth (%) -28.10
IMUC's EPS Growth (%) is ranked higher than
53% of the 236 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. IMUC: -28.10 )
IMUC' s 10-Year EPS Growth (%) Range
Min: -28.1   Max: 81.7
Current: -28.1

-28.1
81.7
» IMUC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

IMUC Guru Trades in

Q4 2013

IMUC Guru Trades in Q4 2013

Paul Tudor Jones 66,303 sh (New)
» More
Q1 2014

IMUC Guru Trades in Q1 2014

Paul Tudor Jones 40,569 sh (-38.81%)
» More
Q2 2014

IMUC Guru Trades in Q2 2014

Paul Tudor Jones 40,569 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with IMUC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.10
IMUC's P/B is ranked higher than
80% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.17 vs. IMUC: 2.10 )
IMUC' s 10-Year P/B Range
Min: 11.5   Max: 53.57
Current: 2.1

11.5
53.57
EV-to-EBIT -3.12
IMUC's EV-to-EBIT is ranked lower than
55% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.10 vs. IMUC: -3.12 )
IMUC' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -3.12

Current Ratio 23.73
IMUC's Current Ratio is ranked higher than
99% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.92 vs. IMUC: 23.73 )
IMUC' s 10-Year Current Ratio Range
Min: 2.64   Max: 76.13
Current: 23.73

2.64
76.13
Quick Ratio 23.73
IMUC's Quick Ratio is ranked higher than
99% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. IMUC: 23.73 )
IMUC' s 10-Year Quick Ratio Range
Min: 2.64   Max: 76.13
Current: 23.73

2.64
76.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.35
IMUC's Price/Net Cash is ranked higher than
98% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. IMUC: 2.35 )
IMUC' s 10-Year Price/Net Cash Range
Min: 1   Max: 93.75
Current: 2.35

1
93.75
Price/Net Current Asset Value 2.35
IMUC's Price/Net Current Asset Value is ranked higher than
97% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. IMUC: 2.35 )
IMUC' s 10-Year Price/Net Current Asset Value Range
Min: 1   Max: 93.75
Current: 2.35

1
93.75
Price/Tangible Book 2.18
IMUC's Price/Tangible Book is ranked higher than
87% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.22 vs. IMUC: 2.18 )
IMUC' s 10-Year Price/Tangible Book Range
Min: 0.96   Max: 77
Current: 2.18

0.96
77
Forward Rate of Return (Yacktman) -21.94
IMUC's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 258 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. IMUC: -21.94 )
IMUC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -21.94

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare: » details
Traded in other countries:KOL.Germany
ImmunoCellular Therapeutics, Ltd. was incorporated with the Secretary of State of Delaware on March 20, 1987 under the name Redwing Capital Corp. On June 16, 1989, it changed its name to Patco Industries, Ltd. and conducted an unrelated business under that name until 1994. On January 30, 2006, it amended its Certificate of InCorporation to change its name to Optical Molecular Imaging, Inc. in connection with its merger on January 31, 2006 with Spectral Molecular Imaging, Inc. On November 2, 2006, it amended its Certificate of InCorporation to change its name to ImmunoCellular Therapeutics, Ltd. ImmunoCellular is a development stage company that is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes peptide based cellular immunotherapies targeting cancer stem cells, cellular immunotherapies targeting cancer antigens, and monoclonal antibodies to diagnose and treat several different cancers. The Company's product candidate is a peptide based off-the-shelf vaccine to target glioblastoma multiforme, the most common brain tumors, for which it plans to file an IND in the third quarter of 2009. This vaccine targets cancer stem cells, which are believed to be roots of cancer, and might be applicable in multiple cancer indications. It has also recently completed a Phase I clinical trial of its dendritic cell based vaccine product candidate to treat glioblastoma multiforme which was initiated in May 2007. In addition, it has several monoclonal antibody product candidates targeting small cell lung cancer, pancreatic cancer, multiple myeloma and ovarian cancer. Through two important acquisitions in the last three years, the Company is building capabilities to develop new cancer immunotherapeutic products harnessing mechanisms of immune system surveillance in the human body. In May 2008, the Company is licensed an additional technology from Cedars-Sinai to target cancer stem cells which might be applicable for brain tumors as well as several other cancer indications. The Company's product candidates include: Active Immunotherapy, which further includes: ICT-121 (cancer stem cell antigen vaccine); ICT-107 (cancer antigen vaccine) and Monoclonal Antibodies: which includes: ICT-109 (Monoclonal Antibody); ICT-037 (Monoclonal Antibody); ICT-69 (Monoclonal Antibody); ICT-Diagnostic-SCLC. The pharmaceutical and biopharmaceutical industry is characterized technological changes and advancements. The United States and other developed countries regulate the preclinical and clinical testing, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution of drugs and biologic products. The United States Food and Drug Administration, under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal statutes and regulations, regulate pharmaceutical and biologic products.
» More Articles for IMUC

Headlines

Articles On GuruFocus.com
creiter note on IMUC Jan 03 2010 


More From Other Websites
ImmunoCellular Therapeutics (IMUC) Jumps: Stock Up 9% Sep 18 2014
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Other Events, Financial Statements and... Sep 17 2014
6:03 am ImmunoCellular Therapeutics receives positive regulatory feedback on ICT-107 dupporting... Sep 17 2014
ImmunoCellular Therapeutics Receives Positive Regulatory Feedback on ICT-107 Supporting Advancement... Sep 17 2014
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Change in Directors or Principal Officers Sep 02 2014
5 Companies Developing New Cancer Drugs Aug 19 2014
IMMUNOCELLULAR THERAPEUTICS, LTD. Financials Aug 19 2014
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 10-Q, Quarterly Report Aug 08 2014
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
ImmunoCellular Therapeutics Announces Second Quarter 2014 Financial Results Aug 07 2014
Q2 2014 IMMUNOCELLULAR THERAPEUTICS Earnings Release - After Market Close Aug 07 2014
ImmunoCellular Therapeutics to Report Financial Results for the Second Quarter 2014 on August 7,... Jul 29 2014
Why Immunotherapies Have Made DelMar's Lead Drug A Necessity In Brain Cancer Jul 15 2014
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 19 2014
Theralase's Cancer Technology Demonstrates Vaccine-Like Properties Jun 16 2014
Positive Trends For ImmunoCellular Therapeutics Jun 09 2014
IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Regulation FD Disclosure, Other Events Jun 04 2014
ImmunoCellular Plans To Move ICT-107 Forward Into Phase III Trials Based On New Sub-Group Analysis... Jun 02 2014
ImmunoCellular upgraded at Roth Capital Jun 02 2014
ImmunoCellular presents updated ICT-107 Phase II data Jun 01 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK